{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:11:14Z","timestamp":1780546274189,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1310,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1124\/jpet.121.000584","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T20:40:17Z","timestamp":1615581617000},"page":"305-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism"],"prefix":"10.1016","volume":"377","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-6436","authenticated-orcid":false,"given":"Young Hee","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Juan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Xi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-4012","authenticated-orcid":false,"given":"Ai-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000584_bib1","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"10.1124\/jpet.121.000584_bib2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2019.2792","article-title":"Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial","volume":"5","author":"Abou-Alfa","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1124\/jpet.121.000584_bib3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrc4029","article-title":"The mathematics of cancer: integrating quantitative models","volume":"15","author":"Altrock","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.121.000584_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10928-018-9590-0","article-title":"Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma","volume":"45","author":"Ande","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.121.000584_bib5","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s10637-011-9764-8","article-title":"Sorafenib exposure decreases over time in patients with hepatocellular carcinoma","volume":"30","author":"Arrondeau","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1124\/jpet.121.000584_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pr.119.018101","article-title":"Transitioning from basic toward systems pharmacodynamic models: lessons from corticosteroids","volume":"72","author":"Ayyar","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.121.000584_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1124\/dmd.120.090621","article-title":"Strain-dependent variability of early discovery small molecule pharmacokinetics in mice: does strain matter?","volume":"48","author":"Barr","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.121.000584_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/bdd.1830","article-title":"A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer","volume":"34","author":"Cheeti","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.121.000584_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/jpet.117.243931","article-title":"Pharmacokinetic\/pharmacodynamic modeling of schedule-dependent interaction between docetaxel and cabozantinib in human prostate cancer xenograft models","volume":"364","author":"Chen","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.000584_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12345","article-title":"Pharmacokinetic-pharmacodynamic model of neutropenia in patients with myeloma receiving high-dose melphalan for autologous stem cell transplant","volume":"7","author":"Cho","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2013.783250","article-title":"Effects of 17\u03b1-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin","volume":"43","author":"Choi","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.121.000584_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.121.000584_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.121.000584_bib14","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","article-title":"Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics","volume":"27","author":"Claret","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.121.000584_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/psp4.12210","article-title":"Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancer","volume":"6","author":"Diekstra","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00685796","article-title":"Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry","volume":"36","author":"Dobbs","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib17","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-016-3018-6","article-title":"Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice","volume":"77","author":"Edginton","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00280-014-2568-8","article-title":"TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial","volume":"74","author":"Erhardt","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bph.12362","article-title":"Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women","volume":"171","author":"Franconi","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.synres.2016.06.001","article-title":"Drug combination in vivo using combination index method: taxotere and T607 against carcinoma HCT-116 xenograft tumor in nude mice","volume":"3","author":"Fu","year":"2016","journal-title":"Synergy"},{"key":"10.1124\/jpet.121.000584_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1208\/s12248-018-0291-9","article-title":"Translational framework predicting tumour response in gemcitabine-treated patients with advanced pancreatic and ovarian cancer from xenograft studies","volume":"21","author":"Garcia-Cremades","year":"2019","journal-title":"AAPS J"},{"key":"10.1124\/jpet.121.000584_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-020-00929-4","article-title":"Population pharmacokinetics of brigatinib in healthy volunteers and patients with cancer","volume":"60","author":"Gupta","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.121.000584_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/jpet.119.264499","article-title":"Pharmacokinetic-pharmacodynamic-efficacy modeling of ONO-7579, a novel pan-tropomyosin receptor kinase inhibitor, in a murine xenograft tumor model","volume":"373","author":"Iida","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.000584_bib24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2011.03963.x","article-title":"Population pharmacokinetic analysis of sorafenib in patients with solid tumours","volume":"72","author":"Jain","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib25","doi-asserted-by":"crossref","first-page":"30742","DOI":"10.18632\/oncotarget.16372","article-title":"Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models","volume":"8","author":"Jian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.121.000584_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1124\/dmd.116.074344","article-title":"Effects of MicroRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice","volume":"45","author":"Jilek","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.121.000584_bib27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.120.000207","article-title":"Pharmacokinetic and pharmacodynamic factors contribute to synergism between let-7c-5p and 5-fluorouracil in inhibiting hepatocellular carcinoma cell viability","volume":"48","author":"Jilek","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.121.000584_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10928-009-9117-9","article-title":"Modeling of tumor growth and anticancer effects of combination therapy","volume":"36","author":"Koch","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.121.000584_bib29","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00280-018-3581-0","article-title":"A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/bjc.1964.55","article-title":"Dynamics of tumor growth","volume":"13","author":"Laird","year":"1964","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.121.000584_bib31","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.121.000584_bib32","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1158\/1078-0432.CCR-07-1475","article-title":"Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients","volume":"14","author":"Li","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.121.000584_bib33","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/aps.2016.55","article-title":"Preclinical PK\/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice","volume":"37","author":"Li","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/jpet.121.000584_bib34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.apsb.2019.10.001","article-title":"Current trends in drug metabolism and pharmacokinetics","volume":"9","author":"Li","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.121.000584_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.31.5.510","article-title":"Diversity of mechanism-based pharmacodynamic models","volume":"31","author":"Mager","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.121.000584_bib36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.121.000584_bib37","doi-asserted-by":"crossref","first-page":"e00016","DOI":"10.1002\/psp4.16","article-title":"Developing exposure\/response models for anticancer drug treatment: special considerations","volume":"4","author":"Mould","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11095-017-2095-5","article-title":"Sequential exposure of bortezomib and vorinostat is synergistic in multiple myeloma cells","volume":"34","author":"Nanavati","year":"2017","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.121.000584_bib39","series-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1124\/jpet.121.000584_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00280-013-2117-x","article-title":"Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice","volume":"71","author":"Pawaskar","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy - an update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejca.2008.10.039","article-title":"Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial","volume":"45","author":"Richly","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.121.000584_bib43","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1016\/j.ejca.2009.09.025","article-title":"Testing additivity of anticancer agents in pre-clinical studies: a PK\/PD modelling approach","volume":"45","author":"Rocchetti","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.121.000584_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/psp4.12057","article-title":"PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor","volume":"5","author":"Schindler","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib45","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","article-title":"Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents","volume":"64","author":"Simeoni","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.121.000584_bib46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","article-title":"Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment","volume":"41","author":"Strumberg","year":"2005","journal-title":"Drugs Today (Barc)"},{"key":"10.1124\/jpet.121.000584_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.000584_bib48","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","article-title":"Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data","volume":"26","author":"Tanaka","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.121.000584_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-013-2208-8","article-title":"A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination","volume":"72","author":"Terranova","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s002800050809","article-title":"Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests","volume":"42","author":"Twelves","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib51","doi-asserted-by":"crossref","first-page":"e1007178","DOI":"10.1371\/journal.pcbi.1007178","article-title":"Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors","volume":"16","author":"Vaghi","year":"2020","journal-title":"PLOS Comput Biol"},{"key":"10.1124\/jpet.121.000584_bib52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-014-2561-2","article-title":"Mechanistic pharmacokinetic\/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates","volume":"74","author":"Wada","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.000584_bib53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.4070","article-title":"ROR-\u03b3 drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer","volume":"22","author":"Wang","year":"2016","journal-title":"Nat Med"},{"key":"10.1124\/jpet.121.000584_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2016.3","article-title":"Combination therapies in oncology","volume":"15","author":"Webster","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.121.000584_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.apsb.2019.11.001","article-title":"Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics","volume":"10","author":"Yi","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.121.000584_bib56","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1002\/jps.24629","article-title":"Semi-mechanism-based pharmacokinetic\/pharmacodynamic model for the combination use of dexamethasone and gemcitabine in breast cancer","volume":"104","author":"Yuan","year":"2015","journal-title":"J Pharm Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:54:26Z","timestamp":1740675266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0022356524270312"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000584","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}